市場調查報告書

高活性療效原料藥的全球市場:各分子類型,各製造技術,各用途,各地區的市場規模,佔有率,展望,機會分析,2020年∼2027年

High Potency Active Pharmaceutical Ingredients Market, By Molecule Type, By Production Technology, By Application, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

出版商 Coherent Market Insights 商品編碼 968762
出版日期 內容資訊 英文 181 Pages
商品交期: 2-3個工作天內
價格
高活性療效原料藥的全球市場:各分子類型,各製造技術,各用途,各地區的市場規模,佔有率,展望,機會分析,2020年∼2027年 High Potency Active Pharmaceutical Ingredients Market, By Molecule Type, By Production Technology, By Application, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
出版日期: 2020年10月01日內容資訊: 英文 181 Pages
簡介

高效活性藥物成分(HPAPI)是抗體-藥物偶聯物的小分子,生物或雜合體,可將細胞毒性小分子與單克隆抗體連接。由於高效能活性藥物成分(HPAPIs)能夠比其他APIs更精確和更有針對性地靶向病變細胞,因此其需求迅速增長,並且被認為是全球範圍內相對有效的癌症和慢性病治療方法。

本報告提供全球高活性療效原料藥市場調查,提供市場力學和法規,各分子類型,各製造技術,各用途,各地區的分析,競爭情形和企業簡介等資訊。

目錄

第1章 調查目的與前提條件

第2章 市場展望

  • 報告概要
  • 市場定義和範圍
  • 摘要整理
  • 市場明細:各分子類型
  • 市場明細:各製造技術
  • 市場明細:各用途
  • 市場機會藍圖

第3章 市場力學,法規,趨勢分析

  • 市場力學
    • 促進因素
    • 阻礙因素
    • 市場機會
  • 影響分析
  • 主要的動向
  • 法規方案
  • PEST分析
  • COVID-19的影響分析

第4章 市場分析:各分子類型

  • 簡介
    • 市場佔有率分析
    • 與前一年同期比較成長率分析
    • 市場區隔趨勢
  • 創新的
  • 非專利

第5章 市場分析:各製造技術

  • 簡介
    • 市場佔有率分析
    • 與前一年同期比較成長率分析
    • 市場區隔趨勢
  • 化學合成
  • 生物科技

第6章 市場分析:各用途

  • 簡介
    • 市場佔有率分析
    • 與前一年同期比較成長率分析
    • 市場區隔趨勢
  • 腫瘤
  • 荷爾蒙
  • 青光眼
  • 其他

第7章 市場分析:各地區

  • 簡介
    • 市場佔有率分析
    • 與前一年同期比較成長率分析
    • 市場區隔趨勢
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 法國
    • 西班牙
    • 俄羅斯
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 東南亞國協
    • 澳洲
    • 韓國
    • 其他
  • 南美
    • 巴西
    • 墨西哥
    • 阿根廷
    • 其他
  • 中東
    • GCC各國
    • 以色列
    • 其他
  • 非洲
    • 北非
    • 中非
    • 南非

第8章 競爭情形

  • 企業簡介
    • Lonza Inc.
    • Novartis International AG
    • BASF AG
    • SEQENS
    • Carbogen Amcis AG
    • Eli Lilly and Company
    • Teva Pharmaceutical Industries Ltd
    • Bristol-Myers Squibb
    • Pfizer Inc.
    • Roche Diagnostics
    • Boehringer Ingelheim
    • Other Players

第9章

目錄

Title:
High Potency Active Pharmaceutical Ingredients Market, By Molecule Type (Innovative, Generic), By Production Technology (Chemical Synthesis, Biotechnology), By Application (Oncology, Hormonal, Glaucoma, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027.

High potency active pharmaceutical ingredients (HPAPIs) are small-molecule, biologic, or hybrids of antibody-drug conjugates, which link a cytotoxic small-molecule to a monoclonal antibody. Demand for high potency active pharmaceutical ingredients (HPAPIs) is rapidly increasing due to its ability to target diseased cells more precisely and selectively than other APIs and is regarded as a relatively more efficient treatment for cancer and chronic diseases such as diabetes and heart diseases, worldwide. According to estimates from the International Agency for Research on Cancer (IARC), in 2012, 14.1 million new cancer cases and 8.2 million cancer deaths were recorded worldwide. This global burden of cancer is expected to account for 21.7 million new cancer cases and cause 13 million deaths by 2030.

Restraints of the Global High Potency Active Pharmaceutical Ingredients Market

Major factors hampering the growth of the high potency active pharmaceutical ingredients market during the forecast period constitutes of high costs, and stringent regulations.

Key features of the study:

  • This report provides in-depth analysis of the global high potency active pharmaceutical ingredients market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2020-2027), considering 2019, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
  • It profiles leading players in the global high potency active pharmaceutical ingredients market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Lonza, Novartis International AG, BASF AG, SEQENS, Carbogen Amcis AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd Bristol-Myers Squibb, Pfizer Inc., Roche Diagnostics, Boehringer Ingelheim, Merck & Co, Bayer AG, Ajinomoto Bio-Pharma Molecule Types, Cambrex Corporation, Minakem, and Sanofi Aventis.
  • Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global high potency active pharmaceutical ingredients market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

  • Global High Potency Active Pharmaceutical Ingredients Market, By Molecule Type:
    • Innovative
    • Generic
  • Global High Potency Active Pharmaceutical Ingredients Market, By Production Technology:
    • Chemical Synthesis
    • Biotechnology
  • Global High Potency Active Pharmaceutical Ingredients Market, By Application:
    • Oncology
    • Hormonal
    • Glaucoma
    • Others
  • Global High Potency Active Pharmaceutical Ingredients Market, By Geography:
    • North America
  • By Molecule Type
    • Innovative
    • Generic
  • By Production Technology
    • Chemical Synthesis
    • Biotechnology
  • By Application
    • Oncology
    • Hormonal
    • Glaucoma
    • Others
  • By Country:
    • U.S.
    • Canada
    • Europe
  • By Molecule Type
    • Innovative
    • Generic
  • By Production Technology
    • Chemical Synthesis
    • Biotechnology
  • By Application
    • Oncology
    • Hormonal
    • Glaucoma
    • Others
  • By Country:
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
  • By Molecule Type
    • Innovative
    • Generic
  • By Production Technology
    • Chemical Synthesis
    • Biotechnology
  • By Application
    • Oncology
    • Hormonal
    • Glaucoma
    • Others
  • By Country:
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
    • Latin America
  • By Molecule Type
    • Innovative
    • Generic
  • By Production Technology
    • Chemical Synthesis
    • Biotechnology
  • By Application
    • Oncology
    • Hormonal
    • Glaucoma
    • Others
  • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Middle East:
  • By Molecule Type
    • Innovative
    • Generic
  • By Production Technology
    • Chemical Synthesis
    • Biotechnology
  • By Application
    • Oncology
    • Hormonal
    • Glaucoma
    • Others
  • By Country:
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
  • By Molecule Type
    • Innovative
    • Generic
  • By Production Technology
    • Chemical Synthesis
    • Biotechnology
  • By Application
    • Oncology
    • Hormonal
    • Glaucoma
    • Others
  • By Country/Region:
    • Central Africa
    • South Africa
    • North Africa
  • Company Profiles
    • Lonza Inc.*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Key Strategies
  • Recent Developments
    • Novartis International AG
    • BASF AG
    • SEQENS
    • Carbogen Amcis AG
    • Eli Lilly and Company
    • Teva Pharmaceutical Industries Ltd
    • Bristol-Myers Squibb
    • Pfizer Inc.
    • Roche Diagnostics
    • Boehringer Ingelheim
    • Other Players

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

    • Research Objectives
    • Assumptions
    • Abbreviations

2. Market Purview

    • Report Description
  • Market Definition and Scope
    • Executive Summary
  • Market Snippet, By Molecule Type
  • Market Snippet, By Production Technology
  • Market Snippet, By Application
    • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

    • Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
    • Impact Analysis
    • Key Developments
    • Regulatory Scenario
    • PEST Analysis
    • COVID-19 Impact Analysis

4. Global High Potency Active Pharmaceutical Ingredients Market, By Molecule Type, 2016 - 2027 (US$ Mn)

    • Introduction
  • Market Share Analysis, 2019 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017-2027
  • Segment Trends
    • Innovative
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Segment Trends
    • Generic
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Segment Trends

5. Global High Potency Active Pharmaceutical Ingredients Market, By Production Technology, 2016 - 2027 (US$ Mn)

    • Introduction
  • Market Share Analysis, 2019 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017-2027
  • Segment Trends
    • Chemical Synthesis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Biotechnology
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)

6. Global High Potency Active Pharmaceutical Ingredients Market, By Application, 2016 - 2027 (US$ Mn)

    • Introduction
  • Market Share Analysis, 2019 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017-2027
  • Segment Trends
    • Oncology
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Hormonal
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Glaucoma
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)

7. Global High Potency Active Pharmaceutical Ingredients Market, By Regions, 2016 - 2027 (US$ Mn)

    • Introduction
  • Market Share Analysis, 2019 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017-2027
  • Segment Trends
    • North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • U.S.
    • Canada
    • Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
    • Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • North Africa
    • Central Africa
    • South Africa

8. Competitive Landscape

    • Company Profiles
  • Lonza Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Novartis International AG
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • BASF AG
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • SEQENS
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Carbogen Amcis AG
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Eli Lilly and Company
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Teva Pharmaceutical Industries Ltd
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bristol-Myers Squibb
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Roche Diagnostics
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Boehringer Ingelheim
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Other Players
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

9. Section

    • References
    • Research Methodology
    • About us and Sales Contact